ClinicalTrials.gg
CompletedNCT02736968Updated Jan 26, 2023Results posted

Auranofin for Giardia Protozoa

A Phase 2 interventional study of Auranofin and Placebo in Amoebic Dysentery and Giardiasis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 2 sites in Bangladesh. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health. This study is designed to compare placebo to once daily doses of 6mg auranofin for adults with amebiasis or giardiasis. A sample size of 68 subjects enrolled with amebiasis (34 per arm) and 68 with giardiasis (34 per arm); Power based on 60 subjects with amebiasis and 60 with giardiasis completing the study.Eligible subjects will be randomly assigned to a treatment group with auranofin (6 mg orally once daily for 5 days for giardiasis or 7 days for amebiasis) compared to a placebo group receiving similar but not identical placebo capsules. Projected duration of subject participation will be approximately 30 days of face to face visits, including the pre-enrollment screening period of up to 4 days. It is anticipated that it will take approximately 3.5 years to finish the study. Primary objectives are: 1) to compare the proportion of subjects with stools positive by rapid Enzyme Immunoassay (EIA) and positive antigen detection EIA for E. histolytica at enrollment with resolution of diarrhea (less than 3 loose stools/24 hrs) by Day 7 for E. histolytica infections. 2) to compare the proportion of subjects with stools positive by rapid EIA and positive antigen detection EIA for Giardia at enrollment with resolution of diarrhea (less than 3 loose stools/24 hrs) by Day 5 for Giardia infections.

Read the detailed description

This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health. This study is designed to compare placebo to once daily doses of 6mg auranofin for adults with amebiasis or giardiasis. A sample size of 68 subjects enrolled with amebiasis (34 per arm) and 68 with giardiasis (34 per arm); Power based on 60 subjects with amebiasis and 60 with giardiasis completing the study. Eligible subjects will be randomly assigned to a treatment group with auranofin (6 mg orally once daily for 5 days for giardiasis or 7 days for amebiasis) compared to a placebo group receiving similar but not identical placebo capsules. Projected duration of subject participation will be approximately 30 days of face to face visits, including the pre-enrollment screening period of up to 4 days. It is anticipated that it will take approximately 3.5 years to finish the study. Primary objectives are: 1) to compare the proportion of subjects with stools positive by rapid Enzyme Immunoassay (EIA) and positive antigen detection EIA for E. histolytica at enrollment with resolution of diarrhea (less than 3 loose stools/24 hrs) by Day 7 for E. histolytica infections. 2) to compare the proportion of subjects with stools positive by rapid EIA and positive antigen detection EIA for Giardia at enrollment with resolution of diarrhea (less than 3 loose stools/24 hrs) by Day 5 for Giardia infections. Secondary objectives for E. histolytica infections are: 1) to compare the proportion of subjects with stools positive by rapid EIA and positive antigen detection EIA for E. histolytica and trophozoites on smear at enrollment with parasitological response (no detection of trophozoites of E. histolytica on microscopic exam) by Day 7; 2) to compare the proportion of subjects with stools positive rapid EIA and positive antigen detection EIA for E. histolytica and trophozoites on smear at enrollment with parasitological response (no detection of trophozoites on microscopic exam or negative antigen detection) by Days 3 and 5; 3) to compare the rate of decrease of trophozoites/cyst load by Quantitative Polymerase Chain Reaction (qPCR) in stools by Days 3, 5, and 7; 4) to compare the proportion of subjects with negative stool antigen tests by days 3, 5, 7, and 14; 5) to compare the proportion of subjects with sustained cure (no detection of trophozoites by microscopic exam) at 14 and 28 days; 6) to compare the proportion of subjects with relapse (same strain) or re-infection (new strain) with positive stools at 14 and 28 days by genotyping the initial vs. subsequent strain; 7) to compare the time to resolution of diarrhea (less than 3 loose stools/24 hours). Secondary objectives for Giardia infections are: 1) to compare the proportion of subjects with parasitological response (no detection of trophozoites on microscopic exam ) on Day 3, and 5; 2) to compare the rate of decrease of trophozoites/cyst load by qPCR in stools by Days 3 and 5; 3) to compare the proportion of subjects with negative stool antigens by days 3 and 5; 4) to compare the proportion of subjects with sustained cure (no detection of trophozoites by microscopic exam) at 14 and 28 days; 5) to compare the proportion of subjects with relapse (same strain) or re-infection (new strain) with positive stools at 14 and 28 days by genotyping the initial vs. subsequent strain; 6) to compare the time to resolution of diarrhea (less than 3 loose stools/24 hours).

02

Conditions studied

  • Amoebic Dysentery
  • Giardiasis

Keywords

  • Amebiasis
  • Auranofin
  • GI Protozoa
  • Giardiasis
  • Placebo-Controlled
  • Reprofiled Drug
  • Single-Blind
03

In context

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,448 studies on the registry; 180 are open to participants now.

Of its 406 completed or terminated interventional studies of FDA-regulated products, 302 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written prior to initiation of any study procedures.
  2. Able to understand and comply with planned study procedures and be available for all study visits.
  3. Male or non-pregnant non-lactating females 18-65 years of age, inclusive. Females of currently using effective methods are eligible.
  4. Amebiasis or giardiasis identified by rapid Enzyme Immunoassay (EIA) and positive antigen detection EIA of stool

    • if a subject is infected with both E. histolytica and Giardia, they will be enrolled in the E. histolytica study arm. Once the Entamoeba study arm is fully enrolled, any subsequent dual infected subjects will be enrolled in the Giardia arm. If a subject is infected with both Giardia and Cryptosporidium, they will not be enrolled.
  5. Has diarrhea (defined as three or more loose stools) in the past 24 hrs, but is assessed to be clinically stable and in otherwise good health

    • as determined by medical history and targeted physical examination, if indicated based on medical history, to evaluate acute or currently ongoing chronic medical diagnoses or conditions that would affect the assessment of eligibility and safety of subjects. Existing medical diagnoses or conditions (except those in the Subject Exclusion Criteria) must be deemed as stable chronic medical conditions. A stable chronic medical condition is defined as no change in prescription medication, dose, or frequency of medication in the last 3 months (90 days) and health outcomes of the specific disease are considered to be within acceptable limits in the last 6 months (180 days). Any change due to change of health care provider, insurance company, or that is done for financial reasons, as long as in the same class of medication, will not be considered a violation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the site principal investigator or appropriate sub-investigator, will not be considered a violation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety. Topical, nasal, and inhaled medications, vitamins, and contraceptives are permitted.
  6. Vital signs (oral temperature, pulse, and blood pressure) are all within normal protocol-defined ranges.
  7. Laboratory tests (blood urea nitrogen, creatinine, (AST), alanine transaminase (ALT), white blood cells, , and ) are all within protocol-defined ranges. Subjects will be eligible for enrollment with the following laboratory values: blood urea nitrogen less than or equal to 30 mg/dL, creatinine less than or equal to 133 umol/L, AST or ALT less than or equal to 70.0 U/L, white cell count between 3.5 and 13.0 inclusive (10\^9/L), platelets between 131 and 550 (10\^9/L), hemoglobin between 11.0 and 18.0 gm/dL inclusive.
  8. Urinalysis with no greater than trace protein. If a high protein is confirmed to be due to menstruation, it should be repeated.
  9. Women of reproductive potential must have a negative urine pregnancy test within 72 hours of starting study medications.

    • Female subjects who are surgically sterile via tubal sterilization, bilateral oophorectomy or hysterectomy who have been for greater than 1 year are not considered to be of reproductive potential.
  10. Female subjects participating in sexual activity that could lead to pregnancy must be using and continue to use highly effective contraception for a total of 4 months after enrollment.

    • Highly effective methods of contraception are defined as having low failure rates (i.e. less than 1 percent per year) when used consistently and correctly and may include, but are not limited to, abstinence from intercourse, monogamous relationship with a vasectomized partner, male condoms with spermicide, diaphragm with spermicide, intrauterine devices, and licensed hormonal methods. Females on effective forms of birth control will continue while on the study and for the follow-up period of 4 months total. The method and compliance of birth control used will be confirmed and documented at all study visits.

Exclusion criteria

Exclusion Criteria:

  1. Known intolerance of auranofin or gold compounds.
  2. Pregnant or breastfeeding women or women of not using effective or who plan to become pregnant or breastfeed at any given time during the study or within 3 months of study completion.
  3. Use of metronidazole within the past 7 days.
  4. Has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
  5. Concurrent participation in other protocols or receipt of an investigational product within the previous 30 days.
  6. History of alcohol or drug abuse within the last five years.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    E. histolytica- Active

    N=34, 6mg auranofin daily x 7 days

    Drug: Auranofin

  • Placebo comparator
    E. histolytica- Placebo

    N=34, 6mg placebo daily x 7 days

    Other: Placebo

  • Experimental
    Giardia- Active

    N=34, 6mg auranofin daily x 5 days

    Drug: Auranofin

  • Placebo comparator
    Giardia- Placebo

    N=34, 6mg placebo daily x 5 days

    Other: Placebo

Interventions

  • Auranofin is a gold-containing chemical salt available as 3mg capsules

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)

    Diarrhea was assessed by self-report at each study visit. Resolution of diarrhea occurred when participants reported less than 3 loose stools in 24 hours.

    Time frame: Day 5

  2. Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)

    Participants provided stool samples on Day 5. Stool samples were assessed for parasitological response by detection of cysts or trophozoites via microscopic exam or a negative antigen test.

    Time frame: Day 5

Secondary outcomes

  1. Proportion of Participants With Negative Giardia Stool Antigens

    Participants provided stool samples on Days 3 and 5. Stool samples were tested for Giardia using antigen detection EIA. Proportions are calculated as the number of participants with negative Giardia stool antigen tests divided by the number of participants with results available.

    Time frame: Day 3 through Day 5

  2. Proportion of Symptomatic Participants With Positive Rapid EIA and Positive Antigen Detection EIA for Giardia and Trophozoites on Smear at Enrollment With Parasitological Response

    Participants provided stool samples on Days 3 and 5. Stool samples were assessed for parasitological response by detection of trophozoites via microscopic exam. Proportions are calculated as the number of participants with parasitological response divided by the number of participants with results available.

    Time frame: Day 3 through Day 5

  3. Proportion of Symptomatic Participants With Sustained Giardia Cure (no Detection of Trophozoites by Microscopic Exam)

    Participants provided stool samples on Days 14 and 28. Stool samples were assessed for sustained Giardia cure by detection of trophozoites via microscopic exam. Proportion is calculated as the number of participants with sustained cure divided by the number of participants with results available.

    Time frame: Day 14 through Day 28

  4. Giardia Trophozoite/Cyst Load by Quantitative Polymerase Chain Reaction (qPCR) in Stools of Symptomatic Participants

    Participants provided stool samples on Days 3 and 5. The Giardia trophozoite/cyst load (parasites/uL) for each group was then assessed by Quantitative Polymerase Chain Reaction (qPCR).

    Time frame: Day 3 through Day 5

  5. Time to Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)

    Diarrhea was assessed by self-report at each study visit. Resolution of diarrhea occurred when participants reported less than 3 loose stools in 24 hours.

    Time frame: Day 1 through Day 28

  6. Proportion of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)

    Participants provided stool samples on Day3. Stool samples were assessed for parasitological response by detection of cysts or trophozoites via microscopic exam or a negative antigen test. Proportions are calculated as the number of participants with parasitological response divided by the number of participants with results available.

    Time frame: Day 3

  7. Giardia Trophozoite/Cyst Load by Quantitative Polymerase Chain Reaction (qPCR) in Stools

    Participants provided stool samples on Days 3 and 5. The Giardia trophozoite/cyst load (parasites/uL) for each group was then assessed by Quantitative Polymerase Chain Reaction (qPCR).

    Time frame: Day 3 through Day 5

  8. Proportion of Asymptomatic Participants With Sustained Giardia Cure (no Detection of Trophozoites by Microscopic Exam)

    Participants provided stool samples on Days 14 and 28. Stool samples were assessed for sustained Giardia cure by detection of cysts or trophozoites via microscopic exam or negative antigen detection. Proportions are calculated as the number of participants with sustained cure divided by the number of participants with results available.

    Time frame: Day 14 through Day 28

  9. Proportion of Participants With Relapse (Same Strain) or Re-infection (New Strain) With Giardia-positive Stools by Genotyping the Initial vs. Subsequent Strain

    Participants provided stool samples on Days 14 and 28. Any stool that was still positive for Giardia or trophozoites at Days 14 and 28 had DNA genotyping of the parasite performed on de-identified specimens of extracted DNA. The genotypes from initial and final isolates were compared to determine relapse and/or re-infection. Proportion is calculated as the number of participants with relapse or re-infection divided by the number of participants with results available.

    Time frame: Day 14 through Day 28

  10. Proportion of Participants With Relapse (Same Strain) or Re-infection (New Strain) With Giardia-positive Stools by Genotyping the Initial vs. Subsequent Strain

    Participants provided stool samples on Days 1, 14 and 28. Participants that were positive for Giardia via antigen detection at Day 1 and had a negative antigen detection test followed by a positive antigen detection test had DNA genotyping of the parasite performed on de-identified specimens of extracted DNA. The genotypes from initial (Day 1) and final isolates (Day 14/28) were compared to determine relapse and/or re-infection. Proportion is calculated as the number of participants with relapse or re-infection divided by the number of participants with results available.

    Time frame: Day 1 through Day 28

07

Results

Posted Jan 26, 2023

Participant flow

Participants were males and non-pregnant females between 18 to 65 years of age, inclusive, with amebiasis or giardiasis. Asymptomatic participants were recruited from the Mirpur community of Bangladesh by a randomized census. Symptomatic participants were identified by a health professional at either icddr,b or Rajshahi Medical College hospitals. Asymptomatic participants were enrolled from 06NOV2016 to 23APR2017. Symptomatic participants were enrolled from 16JAN2018 to 28JAN2021.

Participant flow — Overall Study
MilestoneAsymptomatic E. Histolytica- AuranofinAsymptomatic E. Histolytica- PlaceboAsymptomatic Giardia- AuranofinAsymptomatic Giardia- PlaceboSymptomatic E. Histolytica- AuranofinSymptomatic E. Histolytica- PlaceboSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
Started011716003029
Completed011716002227
Not completed00000082
Withdrew: Lost to follow-up00000052
Withdrew: Covid-19 pandemic00000020
Withdrew: Withdrawal by subject00000010

Outcome measures

PrimaryNumber of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)

Diarrhea was assessed by self-report at each study visit. Resolution of diarrhea occurred when participants reported less than 3 loose stools in 24 hours.

Time frame:
Day 5
Reported as:
Count of participants · Participants
Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)
ParticipantsSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)2828
Statistical analysis
  • Symptomatic Giardia- Auranofin vs Symptomatic Giardia- Placebo · Fisher Exact · p = >0.999 (No adjustment for multiple comparisons was made. The a priori threshold for statistical significance is 0.05.) · Difference in proportions: 0.00 · 95% CI -0.12 to 0.12Adjusted Wald Intervals
PrimaryNumber of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)

Participants provided stool samples on Day 5. Stool samples were assessed for parasitological response by detection of cysts or trophozoites via microscopic exam or a negative antigen test.

Time frame:
Day 5
Reported as:
Count of participants · Participants
Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)
ParticipantsAsymptomatic Giardia- AuranofinAsymptomatic Giardia- Placebo
Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)66
Statistical analysis
  • Asymptomatic Giardia- Auranofin vs Asymptomatic Giardia- Placebo · Fisher Exact · p = >0.999 (No adjustment for multiple comparisons was made. The a priori threshold for statistical significance is 0.05.) · Difference in proportions: 0.00 · 95% CI -0.34 to 0.34Adjusted Wald Intervals
SecondaryProportion of Participants With Negative Giardia Stool Antigens

Participants provided stool samples on Days 3 and 5. Stool samples were tested for Giardia using antigen detection EIA. Proportions are calculated as the number of participants with negative Giardia stool antigen tests divided by the number of participants with results available.

Time frame:
Day 3 through Day 5
Reported as:
Number · proportion of participants
Proportion of Participants With Negative Giardia Stool Antigens
proportion of participantsSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
Day 30.45 (0.28 to 0.62)0.38 (0.23 to 0.56)
Day 50.55 (0.38 to 0.72)0.34 (0.20 to 0.53)
SecondaryProportion of Symptomatic Participants With Positive Rapid EIA and Positive Antigen Detection EIA for Giardia and Trophozoites on Smear at Enrollment With Parasitological Response

Participants provided stool samples on Days 3 and 5. Stool samples were assessed for parasitological response by detection of trophozoites via microscopic exam. Proportions are calculated as the number of participants with parasitological response divided by the number of participants with results available.

Time frame:
Day 3 through Day 5
Reported as:
Number · proportion of participants
Proportion of Symptomatic Participants With Positive Rapid EIA and Positive Antigen Detection EIA for Giardia and Trophozoites on Smear at Enrollment With Parasitological Response
proportion of participantsSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
Day 30.97 (0.81 to 1.00)0.93 (0.77 to 0.99)
Day 50.97 (0.81 to 1.00)1.00 (0.86 to 1.00)
SecondaryProportion of Symptomatic Participants With Sustained Giardia Cure (no Detection of Trophozoites by Microscopic Exam)

Participants provided stool samples on Days 14 and 28. Stool samples were assessed for sustained Giardia cure by detection of trophozoites via microscopic exam. Proportion is calculated as the number of participants with sustained cure divided by the number of participants with results available.

Time frame:
Day 14 through Day 28
Reported as:
Number · proportion of participants
Proportion of Symptomatic Participants With Sustained Giardia Cure (no Detection of Trophozoites by Microscopic Exam)
proportion of participantsSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
Day 140.96 (0.81 to 1.00)0.90 (0.73 to 0.97)
Day 280.96 (0.78 to 1.00)0.89 (0.72 to 0.97)
SecondaryGiardia Trophozoite/Cyst Load by Quantitative Polymerase Chain Reaction (qPCR) in Stools of Symptomatic Participants

Participants provided stool samples on Days 3 and 5. The Giardia trophozoite/cyst load (parasites/uL) for each group was then assessed by Quantitative Polymerase Chain Reaction (qPCR).

Time frame:
Day 3 through Day 5
Reported as:
Mean · log parasite load/uL
Giardia Trophozoite/Cyst Load by Quantitative Polymerase Chain Reaction (qPCR) in Stools of Symptomatic Participants
log parasite load/uLSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
Day 38.6 (7.1 to 10.1)9.2 (8.0 to 10.4)
Day 58.2 (6.8 to 9.6)8.1 (7.1 to 9.2)
SecondaryTime to Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)

Diarrhea was assessed by self-report at each study visit. Resolution of diarrhea occurred when participants reported less than 3 loose stools in 24 hours.

Time frame:
Day 1 through Day 28
Reported as:
Number · days
Time to Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)
daysSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
Time to Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)3 (3.0 to 4.0)3 (NA to NA)
Statistical analysis
  • Symptomatic Giardia- Auranofin vs Symptomatic Giardia- Placebo · Log Rank · p = 0.142 (No adjustment for multiple comparisons was made. The a priori threshold for statistical significance is 0.05.)
SecondaryProportion of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)

Participants provided stool samples on Day3. Stool samples were assessed for parasitological response by detection of cysts or trophozoites via microscopic exam or a negative antigen test. Proportions are calculated as the number of participants with parasitological response divided by the number of participants with results available.

Time frame:
Day 3
Reported as:
Number · proportion with parasitological response
Proportion of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)
proportion with parasitological responseAsymptomatic Giardia- AuranofinAsymptomatic Giardia- Placebo
Proportion of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)0.43 (0.21 to 0.67)0.29 (0.11 to 0.55)
SecondaryGiardia Trophozoite/Cyst Load by Quantitative Polymerase Chain Reaction (qPCR) in Stools

Participants provided stool samples on Days 3 and 5. The Giardia trophozoite/cyst load (parasites/uL) for each group was then assessed by Quantitative Polymerase Chain Reaction (qPCR).

Time frame:
Day 3 through Day 5
Reported as:
Mean · log parasite load/uL
Giardia Trophozoite/Cyst Load by Quantitative Polymerase Chain Reaction (qPCR) in Stools
log parasite load/uLAsymptomatic Giardia- AuranofinAsymptomatic Giardia- Placebo
Day 37.5 (5.0 to 10)9.0 (6.8 to 11.2)
Day 57.1 (4.9 to 9.2)8.5 (6.3 to 10.8)
SecondaryProportion of Asymptomatic Participants With Sustained Giardia Cure (no Detection of Trophozoites by Microscopic Exam)

Participants provided stool samples on Days 14 and 28. Stool samples were assessed for sustained Giardia cure by detection of cysts or trophozoites via microscopic exam or negative antigen detection. Proportions are calculated as the number of participants with sustained cure divided by the number of participants with results available.

Time frame:
Day 14 through Day 28
Reported as:
Number · proportion of participants
Proportion of Asymptomatic Participants With Sustained Giardia Cure (no Detection of Trophozoites by Microscopic Exam)
proportion of participantsAsymptomatic Giardia- AuranofinAsymptomatic Giardia- Placebo
Day 140.29 (0.11 to 0.55)0.21 (0.07 to 0.48)
Day 280.29 (0.11 to 0.55)0.14 (0.03 to 0.41)
SecondaryProportion of Participants With Relapse (Same Strain) or Re-infection (New Strain) With Giardia-positive Stools by Genotyping the Initial vs. Subsequent Strain

Participants provided stool samples on Days 14 and 28. Any stool that was still positive for Giardia or trophozoites at Days 14 and 28 had DNA genotyping of the parasite performed on de-identified specimens of extracted DNA. The genotypes from initial and final isolates were compared to determine relapse and/or re-infection. Proportion is calculated as the number of participants with relapse or re-infection divided by the number of participants with results available.

Time frame:
Day 14 through Day 28
Reported as:
Number · proportion of participants
Proportion of Participants With Relapse (Same Strain) or Re-infection (New Strain) With Giardia-positive Stools by Genotyping the Initial vs. Subsequent Strain
proportion of participantsAsymptomatic Giardia- AuranofinAsymptomatic Giardia- Placebo
Day 14 - Relapse0.58 (0.32 to 0.81)0.75 (0.46 to 0.92)
Day 14 - Re-infection0.33 (0.14 to 0.61)0.25 (0.08 to 0.54)
Day 28 - Relapse0.63 (0.30 to 0.87)0.73 (0.43 to 0.91)
Day 28 - Re-infection0.25 (0.06 to 0.60)0.09 (0.00 to 0.40)
SecondaryProportion of Participants With Relapse (Same Strain) or Re-infection (New Strain) With Giardia-positive Stools by Genotyping the Initial vs. Subsequent Strain

Participants provided stool samples on Days 1, 14 and 28. Participants that were positive for Giardia via antigen detection at Day 1 and had a negative antigen detection test followed by a positive antigen detection test had DNA genotyping of the parasite performed on de-identified specimens of extracted DNA. The genotypes from initial (Day 1) and final isolates (Day 14/28) were compared to determine relapse and/or re-infection. Proportion is calculated as the number of participants with relapse or re-infection divided by the number of participants with results available.

Time frame:
Day 1 through Day 28
Reported as:
Number · proportion of participants
Proportion of Participants With Relapse (Same Strain) or Re-infection (New Strain) With Giardia-positive Stools by Genotyping the Initial vs. Subsequent Strain
proportion of participantsSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
Day 14 - Relapse0.08 (0.00 to 0.38)0.07 (0.00 to 0.32)
Day 14 - Re-infection0.00 (0.00 to 0.28)0.07 (0.00 to 0.32)
Day 28 - Relapse0.11 (0.00 to 0.46)0.07 (0.00 to 0.34)
Day 28 - Re-infection0.00 (0.00 to 0.34)0.14 (0.03 to 0.41)

Adverse events

Collected over Adverse events were collected from the time the participants received study product and continued through study day 29.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asymptomatic E. Histolytica- Placebo0/1 (0%)0/1 (0%)0/1 (0%)
Asymptomatic Giardia- Auranofin0/17 (0%)0/17 (0%)9/17 (52.9%)
Asymptomatic Giardia- Placebo0/16 (0%)0/16 (0%)7/16 (43.8%)
Symptomatic Giardia- Auranofin0/30 (0%)0/30 (0%)0/30 (0%)
Symptomatic Giardia- Placebo0/29 (0%)0/29 (0%)2/29 (6.9%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAsymptomatic E. Histolytica- PlaceboAsymptomatic Giardia- AuranofinAsymptomatic Giardia- PlaceboSymptomatic Giardia- AuranofinSymptomatic Giardia- Placebo
NauseaGastrointestinal disorders0/14/171/160/300/29
AstheniaGeneral disorders0/13/170/160/300/29
RashSkin and subcutaneous tissue disorders0/13/170/160/300/29
Respiratory Tract InfectionInfections and infestations0/11/172/160/300/29
CoughRespiratory, thoracic and mediastinal disorders0/10/172/160/300/29
DiarrhoeaGastrointestinal disorders0/12/170/160/300/29
VertigoEar and labyrinth disorders0/11/171/160/302/29
InfluenzaInfections and infestations0/10/171/160/300/29
Vaginal HaemorrhageReproductive system and breast disorders0/10/171/160/300/29
Abdominal PainGastrointestinal disorders0/11/170/160/300/29

Baseline characteristics

No analyses performed on the following groups due to no participants enrolled: Asymptomatic E. histolytica- Auranofin, Symptomatic E. histolytica- Auranofin, Symptomatic E. histolytica- Placebo. Because only one participant was enrolled in Asymptomatic E. histolytica- Placebo, no analyses were performed.

Age, Categorical
Age, Categorical(Participants)Asymptomatic E. Histolytica- PlaceboAsymptomatic Giardia- AuranofinAsymptomatic Giardia- PlaceboSymptomatic Giardia- AuranofinSymptomatic Giardia- PlaceboTotal
<=18 years000000
Between 18 and 65 years11716302993
>=65 years000000
Age, Continuous
Age, Continuous(years)Asymptomatic E. Histolytica- PlaceboAsymptomatic Giardia- AuranofinAsymptomatic Giardia- PlaceboSymptomatic Giardia- AuranofinSymptomatic Giardia- PlaceboTotal
Mean36 ± 038.6 ± 9.333.5 ± 8.234.2 ± 9.533.4 ± 9.434.6 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Asymptomatic E. Histolytica- PlaceboAsymptomatic Giardia- AuranofinAsymptomatic Giardia- PlaceboSymptomatic Giardia- AuranofinSymptomatic Giardia- PlaceboTotal
Female110100122
Male076302871
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Asymptomatic E. Histolytica- PlaceboAsymptomatic Giardia- AuranofinAsymptomatic Giardia- PlaceboSymptomatic Giardia- AuranofinSymptomatic Giardia- PlaceboTotal
Hispanic or Latino000000
Not Hispanic or Latino11716302993
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Asymptomatic E. Histolytica- PlaceboAsymptomatic Giardia- AuranofinAsymptomatic Giardia- PlaceboSymptomatic Giardia- AuranofinSymptomatic Giardia- PlaceboTotal
American Indian or Alaska Native000000
Asian11716302993
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Asymptomatic E. Histolytica- PlaceboAsymptomatic Giardia- AuranofinAsymptomatic Giardia- PlaceboSymptomatic Giardia- AuranofinSymptomatic Giardia- PlaceboTotal
Bangladesh11716302993
08

Study locations

2 sites
  • International Center for Diarrheal Disease Research Bangladesh - Parasitology
    Dhaka, 1212, Bangladesh
  • Rajshahi Medical College Hospital
    Rajshahi 6000, Bangladesh
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Mar 2021, 52 months.

Results were first posted in Jan 2023, 1 year 10 months after primary completion. A results delay was requested in Feb 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2016
First posted
Apr 13, 2016
StartActual
Nov 6, 2016
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 10, 2021
Results delay requested
Feb 24, 2022
Results first posted
Jan 26, 2023
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02736968
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
Nov 6, 2016
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Results posted
Jan 26, 2023
Last update
Jan 26, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Auranofin

Start the discussion